Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: CD1530 is a selective retinoic acid receptor (RAR gamma) agonist (Kds = 150, 1,500, and 2,750 nM for RAR gamma, RAR beta, and RAR alpha receptors, respectively). It demonstrates transcriptional activity at RAR gamma with an AC50 value of 1.8 nM. It has been used in combination with bexarotene, a retinoid X receptor agonist, to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma.
CD1530 is supplied as a crystalline solid. A stock solution may be made by dissolving the CD1530 in the solvent of choice. CD1530 is soluble at 1 molar equivalent NaOH to 50 mM. We do not recommend storing the aqueous solution for more than one day.
Bernard, B.A., Bernardon, J.-M., Delescluse, C., et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem. Biophys. Res. Commun. 186(2), 977-983 (1992).
Tang, X.-H., Osei-Sarfo, K., Urvalek, A.M., et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc. Natl. Acad. Sci. USA 111(24), 8907-8912 (2014). O HO OH PRODUCT INFORMATION